Navigation Links
New phase II study supports potential of gs-9450 as new treatment option for steatohepatitis
Date:4/16/2010

Vienna, Austria, Thursday 15 April: Results from a multinational phase II study presented today at the International Liver CongressTM 2010 have shown that treatment with the caspase inhibitor GS-9450 can reduce markers of liver damage in patients with non-alcoholic steatohepatitis (NASH the most serious form of non-alcoholic liver disease) as demonstrated by reduced levels of alanine (ALT) and aspartate aminotransferases (AST), hepatic enzymes that indicate cell damage.

GS-9450, a potent inhibitor of caspases-8, -9 and -1, the intra-cellular proteins that initiate programmed cell death (or cell suicide, also known as apoptosis) in damaged cells, is a potential new treatment option for patients with NASH a disease characterised by fat build-up in liver cells with subsequent inflammation resulting in accumulation of scar tissue (fibrosis), cirrhosis and eventual liver failure.

Professor Fabio Marra of the EASL scientific committee commented: "It is encouraging to see that GS-9450-associated reduction of apoptosis and cell damage seen in animal models has translated to a significant patient population, and seems to be consistent with a good tolerability profile in patients from a variety of countries. Further studies are needed to evaluate the action of this therapy on histology and to confirm the drug's efficacy and safety in larger patient populations."

In this double-blind, parallel-group study, patients (n=124, principally male, mean age 45 years, with Body Mass Index (BMI) of >30kg/m2) with biopsy-proven NASH were randomised to receive 1, 5, 10 or 40mg GS-9450 or placebo once daily for 4 weeks. After 4 weeks on treatment, patients in the 40mg treatment group experienced the greatest reduction in ALT and AST levels.

At week four, linear regression of ALT versus GS-9450 dose was highly significant (p<0.0001) with 35% achieving ALT levels within the normal range (7-56 U/L ) compared to 0% at study baseline, and 48% achiev
'/>"/>

Contact: Isabelle Scali
media.easl2010@cohnwolfe.com
44-771-743-5103
European Association for the Study of the Liver
Source:Eurekalert

Page: 1 2

Related medicine news :

1. NASA selects DNA Medicine Institutes Nanoscale Diagnostics Technology for Phase II SBIR
2. PRA International Rolls out Client Access to Oracle(R) RDC for Early Phase Studies
3. Treatment for chronic hepatitis C: A phase II study
4. New Pixantrone Phase III Data to be Presented at the 51st Annual Meeting of the American Society of Hematology
5. InstaMed Achieves Core Phase II Certification to Streamline Provider Access to Consistent Electronic Eligibility and Claim Status
6. Pharmacyclics, Inc. Announces Presentation of Interim Results From Phase I Trial of Its First-In-Human Btk Inhibitor PCI-32765
7. Aetna and WellPoint Achieve CORE Phase II Certification
8. Data from Phase 1 Study Confirm High Response Rate of Micromets Blinatumomab in Patients with Non-Hodgkins Lymphoma
9. Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting
10. Hepregen Corporation Receives SBIR Phase II Grant from the National Science Foundation and Presents Corporate Update at OneMed Forum
11. Synomics Pharma and Bioscience Laboratories Announce Partnership to Provide Topical Clinical Phase 1 Study Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... HealthDay Reporter TUESDAY, Dec. ... Diabetes Association (ADA) call for giving the cholesterol-lowering drugs known ... heart disease. These new standards bring the association in ... Association, which also recommend giving low- or high-dose statins to ... diabetes. "We agree that the decision to start a ...
(Date:12/24/2014)... (PRWEB) December 24, 2014 For chic ladies, ... year. As a part of their Holiday Wish List, ... highlight as perfect ways to accent ladies’ holiday wardrobe by ... Ladies should be all over the discount of 80% off, ... and ready to ship. The company’s chic wedding dresses are ...
(Date:12/24/2014)... MA (PRWEB) December 24, 2014 Dr. ... Dentists from across the nation gathered with US Marines ... Dinner to raise funds for the Toys for Tots ... hundreds of thousands of new books and audio books ... go to underprivileged children this Christmas. It represents another ...
(Date:12/24/2014)... December 24, 2014 The report offers ... to the various market dynamics such as the key ... arthroscopy, the wait time for U.S. sports medicine, the ... market, and the challenges faced by the market. , ... , The report also provides an overview of ...
(Date:12/24/2014)... Verde Pointe Dental Associates 2014 Ugly Holiday Sweater Contest ... Christmas sweater lit up, but this years overall color and ... Wilson for the second year in a row. She's ... "She took pictures of the entire staff and glued them ... "Every year I enjoy stopping by the dental clinic and ...
Breaking Medicine News(10 mins):Health News:Nearly All Diabetics Should Be on Cholesterol-Lowering Drugs: Experts 2Health News:Nearly All Diabetics Should Be on Cholesterol-Lowering Drugs: Experts 3Health News:Angeldress.co.uk Starts Its Big Sales by Offering Various Kinds of Cheap Clothes and Fashion Accessories 2Health News:Dr. Svetlana Gomer, MGS Tewksbury Dental and Other Dentists Working With the U.S. Marines Strike Again In the Battle Against Illiteracy 2Health News:Dr. Svetlana Gomer, MGS Tewksbury Dental and Other Dentists Working With the U.S. Marines Strike Again In the Battle Against Illiteracy 3Health News:Sports Medicine Market Report 2014: Global Industry Analysis, Share, Size, Trends, Growth and Forecast report 2Health News:Verde Pointe Dental Associates Announces the 2014 Ugly Sweater Holiday Contest Winner 2
... SPRINGFIELD, Mass., Sept. 3 MassMutual,s Retirement Services ... its growing Taft-Hartley business: , , ... , William (Bill) Erlandson joined ... Scott Buffington, national sales manager for MassMutual Retirement Services ...
... LOS ANGELES, Sept. 3 Saddle Ranch Productions, ... its feature film "Rock and Roll-The Movie" last month, ... documentary entitled "Dietary Supplements, Yes? No? Maybe?" (working title ... investigates America,s fascination and love affair with dietary supplements. ...
... , SEATTLE, Sept. 3 As one of ... surgery, Swedish Medical Center is home to the fastest-growing and ... the multidisciplinary robot-assisted surgical program in 2005 and has since ... program in the region. , , To ...
... , , BRANCHVILLE, N.J., Sept. 3 Selective ... appointments by its subsidiary, Selective Insurance Company of America ("Selective"): ... GA) to senior vice president, underwriting officer for Mid-Market & Large ... he was senior vice president, president Field Operations East for CNA ...
... , FREDERICKSBURG, Va., Sept. 3 Radiologic ... its practice, which now totals 29 physicians with extensive training ... Ed Swager, chief executive officer for RAF, attributes the ... , "We are expanding services to a growing ...
... 3 The following is being released by the U.S. Census Bureau: ... ) , , What: The U.S. Census ... its annual report: Income, Poverty, and Health Insurance Coverage in the ... the Current Population Survey (CPS). , , The ...
Cached Medicine News:Health News:MassMutual Retirement Services Adds to Taft-Hartley Sales Team 2Health News:MassMutual Retirement Services Adds to Taft-Hartley Sales Team 3Health News:Saddle Ranch Productions Announces New Releases 2Health News:Video: Swedish Medical Center Adds Two New da Vinci Surgical Systems to Support Robot-Assisted Surgical Team 2Health News:Selective Insurance Group Announces Officer Appointments 2Health News:Selective Insurance Group Announces Officer Appointments 3Health News:Radiologic Associates of Fredericksburg Hires Four New Physicians 2Health News:Census Bureau News Media Advisory: Census Bureau to Announce Findings for Income, Earnings, Poverty and Health Insurance Coverage 2
(Date:12/24/2014)... , Dec. 23, 2014 Tianyin Pharmaceutical ... that specializes in patented biopharmaceutical, modernized traditional Chinese ... (API) today announced that the Company achieved the ... Manufacturing Practice (GMP) certificate of TPI,s Qionglai Facility ... (CFDA). The public notice period is a significant ...
(Date:12/24/2014)... and RALEIGH, N.C. , Dec. ... Endo International plc (NASDAQ: ENDP ) (TSX: ... BDSI ) announced today that they have submitted a ... to the U.S. Food and Drug Administration (FDA).  Buprenorphine ... of pain severe enough to require daily, around-the-clock, long-term ...
(Date:12/22/2014)... , Dec. 22, 2014  CytoSorbents Corporation ... its CytoSorb® blood purification technology to help fight ... in 28 countries worldwide, today announced the appointment ... MD, FACS, as its Senior Vice President of ... Dr. Di Russo is an ...
Breaking Medicine Technology:TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5
... Endoscopy, Inc.,s (OTCPK: SNDY) is pleased to announce that ... of $73,895.  Solos Endoscopy has consummated agreements which resulted ... Three Months period ending September 30, 2011.  The signed ... reduction of ongoing expenses by approximately $40,000 per quarter. ...
... Health Company (FHCO- NASDAQ-CM) today announced that its exclusive distributor ... (PTY) Ltd., has received an order from the RSA Department ... for delivery as soon as possible. Shipments against the order ... Parrish, Chairman and C.E.O. of The Female Health Company, noted ...
Cached Medicine Technology:Solos Endoscopy Finishes the 3rd Quarter With a Net Profit 2The Female Health Company's Distributor, Sekunjalo Investments Corporation (PTY) Ltd., Receives Order for 5 Million FC2 Female Condoms From the Republic of South Africa Department of Health 2The Female Health Company's Distributor, Sekunjalo Investments Corporation (PTY) Ltd., Receives Order for 5 Million FC2 Female Condoms From the Republic of South Africa Department of Health 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: